Biotechnology > Industries > Ernst & Young - Ernst & Young - Korea

As Washington changes direction, many question whether reform policies will present new opportunities or risks for the pharma, biotech, and medtech sectors. Watch our webcast to hear the views of industry leaders, including Billy Tauzin, President of PhRMA, Jim Greenwood, President of the Biotechnology Industry Organization and Brett Loper, Senior Executive Vice President, Government Affairs from AdvaMed.

How can you manage your company through the recession and position yourself for growth? After interviewing thousands of life sciences executives, we identified some overarching themes. From managing risks to improving capital allocation, we reveal the lessons that could mean the difference between surviving and thriving in the new economic environment.

How are life sciences companies weathering the financial crisis? Working with the Economist Intelligence Unit, we surveyed executives on the steps they’re taking to contend with their ever-mounting pressures. While the industry faced strong headwinds before the economic downturn, our findings highlight key transformational issues and confirm the crisis intensified the need for change. Discover which strategic responses are topping their agendas and see how yours compare (pdf, 281kb).

A deep funding drought. Depressed valuations. Demanding regulators and payors. These are challenging times. But are they unprecedented? Ernst & Young’s 23rd annual biotechnology report reveals how firms are responding with business strategies, new funding sources and creative deals. It also provides historical context, comprehensive data and insightful analysis to show how the business of biotech is going beyond business as usual, and what it means for you.

As industry regulations become more stringent, government and private insurers are placing unprecedented pressures on life sciences companies to demonstrate value for the products they develop. Not surprisingly, this challenge topped the list of the 10 most pressing risks facing the life sciences industry in 2009. Read the press release and report (pdf, 4.61M) for steps which can be taken now to address top risks.